Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, retrospective chart review study analysing safe and efficacy anticoagulant options in patients with atrial fibrillation or venous thromboembolism weighing ≥ 120 kg or BMI ≥ 40 kg/m2

Next Previous
Trial Profile

A single-center, retrospective chart review study analysing safe and efficacy anticoagulant options in patients with atrial fibrillation or venous thromboembolism weighing ≥ 120 kg or BMI ≥ 40 kg/m2

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism
  • Focus Therapeutic Use

Most Recent Events

  • 30 Mar 2021 Results (n=318) comparing the safety and efficacy of DOACs in patients with nonvalvular atrial fibrillation (NVAF) and weighing greater than or equal to120 kg with those weighing less than120 kg, published in the American Journal of Cardiovascular Drugs
  • 23 May 2020 New trial record
  • 30 Mar 2020 Results presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top